MedTrace Logo

Gallium Ga 68 DOTA-NeoBOMB1 and Gallium Ga 68 PSMA-R2 PET/MRI in Diagnosing Participants With Recurrent Prostate Cancer

NCT03698370 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 27

Last updated 2024-01-30

Study results available
· View outcomes & findings →

Summary

This phase II trial studies how well gallium Ga 68 DOTA-NeoBOMB1 and gallium Ga 68 PSMA-R2 positron emission tomography (PET)/magnetic resonance imaging (MRI) work in diagnosing participants with prostate cancer that has come back. Diagnostic procedures, such as gallium Ga 68 DOTA-NeoBOMB1 and gallium Ga 68 PSMA-R2 PET/MRI, may help find and diagnose prostate cancer and find out how far the disease has spread.

Conditions

  • Prostate Adenocarcinoma
  • PSA Progression
  • Recurrent Prostate Carcinoma

Interventions

DRUG

Gallium Ga 68 DOTA-NeoBOMB1

Administered intravenously (IV)

DEVICE

Gallium Ga 68 PSMA-R2

Administered intravenously (IV)

Sponsors & Collaborators

  • Andrei Iagaru

    lead OTHER

Principal Investigators

  • Andrei Iagaru · Stanford Cancer Institute Palo Alto

Study Design

Allocation
RANDOMIZED
Purpose
DIAGNOSTIC
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-12-15
Primary Completion
2022-02-11
Completion
2022-02-11
FDA Drug
Yes
FDA Device
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03698370 on ClinicalTrials.gov